Global High Potency Active Pharmaceutical Ingredients (HPAPIs) Market 2023-2029

March 2023 | 82 pages | ID: G53EFDFD8A2DEN
Gen Consulting Company

Abstracts

High potency active pharmaceutical ingredients (HPAPIs) are drugs that require very small doses to be effective. They are typically used to treat diseases such as cancer and autoimmune disorders. HPAPIs are often synthesized through complex chemical processes and require specialized handling techniques due to their high potency and toxicity. The global HPAPIs market is likely to register a CAGR of over 8.25% with an incremental growth of USD 15.6 billion during the forecast period 2023-2029. HPAPIs are used in the development of targeted therapies, which focus on specific disease pathways, resulting in more effective and fewer side effects. This demand for targeted therapies is one of the significant drivers of the HPAPI market. There is a growing interest in the development of high-quality, safe, and effective HPAPI drugs. Government agencies, such as the US FDA, are issuing guidelines on the manufacturing, handling, and use of these drugs, providing a favorable regulatory environment for HPAPIs.HPAPIs are used in the development of targeted therapies, which focus on specific disease pathways, resulting in more effective and fewer side effects. This demand for targeted therapies is one of the significant drivers of the HPAPI market. There is a growing interest in the development of high-quality, safe, and effective HPAPI drugs. Government agencies, such as the US FDA, are issuing guidelines on the manufacturing, handling, and use of these drugs, providing a favorable regulatory environment for HPAPIs.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global HPAPIs market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, synthesis, manufacturer, application, and region. The global market for HPAPIs can be segmented by product: generic HPAPIs, innovative HPAPIs. According to the research, the innovative HPAPIs segment had the largest share in the global HPAPIs market. HPAPIs market is further segmented by synthesis: biotech HPAPIs, synthetic HPAPIs. In 2022, the synthetic HPAPIs segment made up the largest share of revenue generated by the HPAPIs market. Based on manufacturer, the HPAPIs market is segmented into: captive HPAPI manufacturers, merchant HPAPI manufacturers. Among these, the captive HPAPI manufacturers segment was accounted for the highest revenue generator in 2022. On the basis of application, the HPAPIs market also can be divided into: glaucoma, hormonal imbalance, oncology, others. The oncology segment captured the largest share of the market in 2022. HPAPIs market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.

Market Segmentation
By product: generic HPAPIs, innovative HPAPIs
By synthesis: biotech HPAPIs, synthetic HPAPIs
By manufacturer: captive HPAPI manufacturers, merchant HPAPI manufacturers
By application: glaucoma, hormonal imbalance, oncology, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides analysis of the key companies of the industry and their detailed company profiles including AbbVie Inc., Albany Molecular Research, Inc. (AMRI), BASF SE, C.H. Boehringer Sohn AG & Co. KG, Carbogen Amcis AG, Cipla Limited, Corden Pharma GmbH, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Lonza Group AG, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, SK Biotek Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, Viatris Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global HPAPIs market.
To classify and forecast the global HPAPIs market based on product, synthesis, manufacturer, application, region.
To identify drivers and challenges for the global HPAPIs market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global HPAPIs market.
To identify and analyze the profile of leading players operating in the global HPAPIs market.

Why Choose This Report
Gain a reliable outlook of the global HPAPIs market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY PRODUCT

Generic HPAPIs
Innovative HPAPIs

PART 6. MARKET BREAKDOWN BY SYNTHESIS

Biotech HPAPIs
Synthetic HPAPIs

PART 7. MARKET BREAKDOWN BY MANUFACTURER

Captive HPAPI manufacturers
Merchant HPAPI manufacturers

PART 8. MARKET BREAKDOWN BY APPLICATION

Glaucoma
Hormonal imbalance
Oncology
Others

PART 9. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 10. KEY COMPANIES

AbbVie Inc.
Albany Molecular Research, Inc. (AMRI)
BASF SE
C.H. Boehringer Sohn AG & Co. KG
Carbogen Amcis AG
Cipla Limited
Corden Pharma GmbH
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche AG
Lonza Group AG
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi SA
SK Biotek Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
The Bristol-Myers Squibb Company
Viatris Inc.

DISCLAIMER